<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273542</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00058-31</org_study_id>
    <nct_id>NCT04273542</nct_id>
  </id_info>
  <brief_title>Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening</brief_title>
  <acronym>ICRG0101</acronym>
  <official_title>Multicenter Large-scale Validation Study of the Interest of Broadband Spectroscopy Analysis (Femto/Attosecond by Infrared Laser) on Liquid Biopsies in Breast Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Max Planck d'optique quantique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate the interest of broadband spectroscopy analysis
      (femto/attosecond by infrared laser) on liquid biopsies in breast cancer screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will have one or more liquid biopsy during the follow-up according to the cohort
      and have a mammogram at the same time.

      Biopsies will be analysed by broadband spectroscopy in order to compare the results to
      mammogram result.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of the value of molecular profiling analysis in broadband laser spectroscopy on liquid biopsies for breast cancer screening</measure>
    <time_frame>Comparison between the different cohorts at (T0 : inclusion) and the others visits (T1:+1year; T2: +2years; T3 : +3years; T4:+4years; T5: 5years)</time_frame>
    <description>To validate the value of molecular profiling analysis in broadband laser spectroscopy on liquid biopsies for breast cancer screening by comparing a cohort of patients with localized breast cancer (Stage I/II) to a cohort of women without breast cancer from organized or individual age-matched screening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlating the results of high-speed laser spectroscopy analysis on liquid biopsies with mammography data (ACR 0-5)</measure>
    <time_frame>T0: inclusion; T1:+1year; T2: +2years; T3 : +3years; T4:+4years; T5: 5years</time_frame>
    <description>The results of high-speed laser spectroscopy analysis on liquid biopsies will be correlated with mammography data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate detection rate of both breast cancer screening methods (spectroscopy/mammography) for control cohort</measure>
    <time_frame>T0 : inclusion; T2 : +2 years; T4: +4years</time_frame>
    <description>Estimate the rate of detection of breast cancer occurring within 5 years of examination in the control group according to the reference method (mammography) and the innovative method (&quot;n-variable molecular profiles&quot;) from the baseline analysis performed at Max Planck Institute and algorithmic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the role of confounding factors in the structure of molecular profiles derived from broadband laser spectroscopy</measure>
    <time_frame>T0: inclusion; T1:+1year; T2: +2years; T3 : +3years; T4:+4years; T5: 5years</time_frame>
    <description>To study the confounding role of hormonal status and concomitant inflammatory states in the structure of molecular profiles derived from broadband laser spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of BRCA1/2 patients molecular profiles with control and patient cohorts derived from broadband laser spectroscopy</measure>
    <time_frame>T0: inclusion; T1:+1year; T2: +2years; T3 : +3years; T4:+4years; T5: 5years</time_frame>
    <description>To study the molecular profiles derived from broadband laser spectroscopy on liquid biopsies in a cohort of high-risk women (BRCA1/2) not carrying breast cancer, and to compare their positioning in relation to the 2 main cohorts of the study (patients carrying breast cancer without mutation and healthy controls).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>BRCA1 Mutation</condition>
  <condition>BRCA2 Mutation</condition>
  <arm_group>
    <arm_group_label>Control cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this cohort, women recruited participated to organised breast cancer screening. They must not have breast cancer.
They will have 3 liquid biopsy : the first at inclusion and then at each mammogram every two years (organised breast cancer screening).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this cohort, women for who a breast cancer has been diagnose will be included.
Only one liquid biopsy will be collected before any treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this cohort, women with high risk of BRCA1/2 mutation but without breast cancer.
6 liquid biopsies will be collected : each year after inclusion during 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liquid biopsy</intervention_name>
    <description>Blood sample collection during follow-up of the three cohorts of patients</description>
    <arm_group_label>Control cohort</arm_group_label>
    <arm_group_label>Exploratory cohort</arm_group_label>
    <arm_group_label>Patient cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        *For all participants :

          -  Adult woman capable of giving informed consent to research participation

          -  Affiliation to the French social security system

             &gt;For Control cohort:

          -  Woman participating in organised screening or benefiting from individual follow-up,
             eligible as such for a mammogram

             &gt;For Patient cohort:

          -  woman with invasive breast cancer T0N1, T1N0-1, T2N0-1 (histologically proven) at
             inclusion and before any cancer treatment

             &gt;For Exploratory cohort:

          -  woman carrying the BRCA1/2 mutation, followed according to standard recommendations

        Exclusion Criteria:

          -  For all participants :

               -  Refusal to participate

               -  Reluctant or unable to comply with study requirements

               -  Pregnant or breastfeeding woman

               -  Patients with Stage III/IV or Bilateral Breast Cancer

          -  For Control cohort:

               -  Breast cancer suspected at mammography before liquid biopsy*

          -  For Exploratory cohort:

               -  Concomitant breast cancer

               -  History of breast cancer

                    -  At inclusion visit, woman for who a breast cancer will be suspected at
                       mammography will be include in Patient cohort after an histological proof of
                       breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique PENAULT-LLORCA, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angeline GINZAC, PhD</last_name>
    <phone>0463663337</phone>
    <phone_ext>+33</phone_ext>
    <email>angeline.ginzac@clermont.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie THIVAT, PhD</last_name>
    <phone>0473278029</phone>
    <phone_ext>+33</phone_ext>
    <email>emilie.thivat@clermont.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Joseph GLIGOROV, Md, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Joseph GLIGOROV, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Joseph GLIGOROV, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Joseph GLIGOROV, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean PERRIN</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Puy De Dome</state>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Angeline GINZAC, PhD</last_name>
      <phone>0463663337</phone>
      <phone_ext>+33</phone_ext>
      <email>angeline.ginzac@clermont.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Frédérique PENAULT-LLORCA, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Chataigneraie (Selimed 63)</name>
      <address>
        <city>Beaumont</city>
        <state>Puy De Dôme</state>
        <zip>63110</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno De FRAISSINETTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno De FRAISSINETTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle Santé République</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Puy De Dôme</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benoit MEUSUROLLE, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Benoit MEUSUROLLE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>broadband spectroscopy laser</keyword>
  <keyword>liquid biospsies</keyword>
  <keyword>cancer screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

